SCHEMBL5247129

SCHEMBL5247129

O=C(O)c1ccc(NS(=O)(=O)c2ccc(Cl)c3nonc23)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORA P35398 1/20 0.64
RORC P51449 1/20 0.64
NR1H2 P55055 1/20 0.64
MAPK1 P28482 1/20 0.59
IKBKB O14920 1/20 0.56
POLB P06746 2/20 0.53
HSD17B10 Q99714 1/20 0.53
PFKFB3 Q16875 1/20 0.52
TDP1 Q9NUW8 2/20 0.51
GAA P10253 1/20 0.50
HTT P42858 2/20 0.48
WDR5 P61964 1/20 0.47
TSHR P16473 2/20 0.47
ALDH1A1 P00352 2/20 0.47
KMT2A Q03164 5/20 0.46
MEN1 O00255 4/20 0.46
MAPT P10636 1/20 0.46
ITGA1 P56199 1/20 0.46
NLRP3 Q96P20 1/20 0.46
CASP6 P55212 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5284618 0.86 RORA (0.60) RORARORCNR1H2MAPK1IKBKB
SCHEMBL12334560 0.78 RORA (1.00) RORARORCNR1H2MAPK1IKBKB
SCHEMBL6395791 0.77 GSTP1 (0.51) RORARORCNR1H2MAPK1IKBKB
SCHEMBL6388989 0.77 GSTP1 (0.48) RORARORCNR1H2MAPK1IKBKB
SCHEMBL5244028 0.77 MYC (0.51) IKBKBGAAHTTTSHRALDH1A1
SCHEMBL5299664 0.77 RORA (0.61) RORARORCNR1H2POLBPFKFB3
SCHEMBL6389762 0.76 GAA (0.45) RORARORCNR1H2MAPK1IKBKB
SCHEMBL6394345 0.76 ACLY (0.56) RORARORCNR1H2HSD17B10PFKFB3
SCHEMBL5279927 0.73 PFKFB3 (0.62) RORARORCNR1H2POLBPFKFB3
SCHEMBL6392848 0.73 ALDH1A1 (0.55) GAAHTTTSHRALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US claimed
WO-2008115259-A2 DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES RIGEL PHARMACEUTICALS, INC. (US) 2008-09-25 WO disclosed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP RORA 2756/4885RORC 2031/4885NR1H2 2148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.